Roche Sees Biomarker Data As Support For Immuno-Oncology Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
Use of PD-L1 expression as a biomarker may be up for debate at ASCO, but Roche assures analysts that proper application will unlock its combination-heavy development strategy.
You may also be interested in...
IO Biomarkers: Where Do We Stand In 2017?
Survey of recent literature shows breadth and quality of early research activity aimed at developing biomarkers to predict response to PD-1 and CTLA-4 checkpoint inhibitors.
Bristol’s New Launches Hit Reality As New Product Portfolio Forecast Is Revised
With slower than expected sales of some newer products, Bristol lowered mid-term guidance for its new product portfolio and extended the timeline for reaching the goal to 2026.
A Momentous Day For DMD: Sarepta’s Elevidys Is First Gene Therapy Approved
The US FDA granted an accelerated approval to Sarepta’s Elevidys, the first gene therapy to be approved for some children with Duchenne muscular dystrophy.